Misplaced Pages

Botanix Pharmaceuticals

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Australian pharmaceutical company
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (October 2015)
This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. Please help improve it by replacing them with more appropriate citations to reliable, independent, third-party sources. (January 2021) (Learn how and when to remove this message)
(Learn how and when to remove this message)

Botanix Pharmaceuticals Limited
Company typeListed Public Company
Traded asASX: BOT
IndustryBiotechnology
HeadquartersPerth, Western Australia, and Philadelphia, USA
Area servedGlobal
Key people
  • Vince Ippolito, President and executive chairman
  • Matt Callahan, Founder and executive director
  • Dr Stewart Washer, Director
  • Dr Bill Bosch, Chief scientific officer and executive director
  • Danny Sharp, Non-executive director
ProductsBTX 1503 | For the treatment of moderate to severe acne

BTX 1702 | For the treatment of rosacea BTX 1204A | For the treatment of moderate atopic dermatitis

BTX 1801 | For use in a variety of antimicrobial applications
Websitewww.botanixpharma.com

Botanix Pharmaceuticals is listed on the Australian Securities Exchange with the issue code BOT. The Company is headquartered in Perth, Western Australia and Philadelphia, USA. It is a clinical stage synthetic cannabinoid company, focusing on the compound Cannabidiol. The company has two separate development platforms, dermatology and antimicrobial. Botanix also has an exclusive license to use a proprietary drug delivery system Permetrex, for direct skin delivery of active pharmaceuticals which is utilised in all of their programs.

Research

Botanix Pharmaceuticals product pipeline currently includes four programs for treatment of serious skin diseases:

Dermatology

  • BTX 1503, for the treatment of moderate to severe acne
  • BTX 1702, for the treatment of rosacea
  • BTX 1204A, for the treatment of moderate atopic dermatitis

Antimicrobial

  • BTX 1801, for use in a variety of antimicrobial applications

References

  1. "Synthetic cannabinoids".
  2. "Cannabinoid".
  3. "Cannabidiol".
  4. "Technology – Botanix Pharmaceuticals".
  5. "Pipeline – Botanix Pharmaceuticals".

External links

Western Australia
General Western Australia
Regions
Cities and towns
Western Australia portal
Categories:
Botanix Pharmaceuticals Add topic